Compass Therapeutics Inc.
(CMPX)
undefined
undefined%
At close: undefined
1.46
0.34%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases.
The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1.
The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics Inc.
| Country | United States |
| IPO Date | Apr 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Dr. Thomas J. Schuetz M.D., Ph.D. |
Contact Details
Address: 80 Guest Street Boston, Massachusetts United States | |
| Website | https://www.compasstherapeutics.com |
Stock Details
| Ticker Symbol | CMPX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001738021 |
| CUSIP Number | 20454B104 |
| ISIN Number | US20454B1044 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Thomas J. Schuetz M.D., Ph.D. | Chief Executive Officer |
| Anna Gifford | Communications Manager |
| Dr. James Kranz Ph.D. | Vice President and Head of Chemistry Manufacturing & Controls |
| Dr. Minori Rosales M.D., Ph.D. | Senior Vice President & Head of Clinical Development |
| Jonathan Anderman J.D. | Vice President, Head of Legal & Corporate Secretary |
| Karin Herrera B.A. | Vice President & Head of Clinical Operations |
| Vered Bisker-Leib MBA, Ph.D. | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 4 | Filing |
| Dec 10, 2024 | 3 | Filing |
| Dec 10, 2024 | 3 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 8-K | Current Report |
| Aug 30, 2024 | S-3 | Filing |
| Aug 14, 2024 | 4 | Filing |
| Aug 12, 2024 | 10-Q | Quarterly Report |
| Aug 12, 2024 | 8-K | Current Report |